par Katlama, Christine;Esposito, Roberto;Gatell, Jose;Goffard, Jean-Christophe 
;Grinsztejn, Beatriz;Pozniak, Anton;Rockstroh, Jürgen;Stoehr, Albrecht;Vetter, Norbert;Yeni, Patrick;Parys, Wim;Vangeneugden, Tony;POWER 1 study group,
Référence AIDS, 21, 4, page (395-402)
Publication Publié, 2007-02
;Grinsztejn, Beatriz;Pozniak, Anton;Rockstroh, Jürgen;Stoehr, Albrecht;Vetter, Norbert;Yeni, Patrick;Parys, Wim;Vangeneugden, Tony;POWER 1 study group, Référence AIDS, 21, 4, page (395-402)
Publication Publié, 2007-02
Article révisé par les pairs
| Résumé : | The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor (PI) TMC114 (darunavir) in treatment-experienced HIV-1-infected patients. |
